Journal article
Is there still a place for docetaxel rechallenge in prostate cancer?
World journal of clinical oncology, Vol.6(5), pp.99-103
10/10/2015
DOI: 10.5306/wjco.v6.i5.99
PMID: 26468445
Abstract
Three-weekly docetaxel plus prednisone is the standard first-line cytotoxic treatment for patients with metastatic castrate-resistant prostate cancer (mCRPC). Today, several new treatment options are available for patients with tumor progression after first-line docetaxel: Abiraterone, enzalutamide, cabazitaxel, sipuleucel-T immunotherapy, and the radionuclide radium-223. However, despite the evolving scenario in CRPC treatment, the optimal sequencing of the innovative therapies remains unclear. The reintroduction of docetaxel at the occurrence of disease progression after a drug holiday (docetaxel rechallenge) was often proposed, and this chemotherapeutic agent showed to maintain antitumor activity in mCRPC patients. Docetaxel rechallenge may still constitute a valid treatment option mainly for patients with favorable response to first-line docetaxel, at least > 3 mo progression-free interval, age less than 75 years, good performance status, and acceptable docetaxel toxicity. The risk of cumulative toxicity must be evaluated, since sensory neuropathy, nail disorders and fatigue might occur on docetaxel rechallenge.
Details
- Title: Subtitle
- Is there still a place for docetaxel rechallenge in prostate cancer?
- Creators
- Roberto Petrioli - University of SienaEdoardo Francini - Univ Rome, Policlin Umberto Hosp 1, Med Oncol Unit, I-00161 Rome, ItalyGiandomenico Roviello - University of Siena
- Resource Type
- Journal article
- Publication Details
- World journal of clinical oncology, Vol.6(5), pp.99-103
- DOI
- 10.5306/wjco.v6.i5.99
- PMID
- 26468445
- ISSN
- 2218-4333
- eISSN
- 2218-4333
- Publisher
- Baishideng Publishing Group Inc
- Number of pages
- 5
- Language
- English
- Date published
- 10/10/2015
- Academic Unit
- Internal Medicine
- Record Identifier
- 9985221242602771
Metrics
1 Record Views